-
公开(公告)号：US12122814B2
公开(公告)日：2024-10-22
申请号：US18501584
申请日：2023-11-03
发明人： John Mumm
IPC分类号： C07K14/54 , A61K38/00 , A61K39/395 , A61P35/00 , A61P37/06 , C07K14/55 , C07K16/10 , C07K16/28 , C07K16/32 , C07K16/46 , A61K39/00
CPC分类号： C07K14/5428 , A61P35/00 , A61P37/06 , C07K14/5406 , C07K14/55 , C07K16/10 , C07K16/1045 , C07K16/2803 , C07K16/2863 , C07K16/2896 , C07K16/32 , C07K16/464 , A61K38/00 , A61K2039/505 , A61K2039/545 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/92 , C07K2319/30
摘要： The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
-
公开(公告)号：US12116392B2
公开(公告)日：2024-10-15
申请号：US18501884
申请日：2023-11-03
发明人： John Mumm
IPC分类号： C07K14/54 , A61K38/00 , A61K39/395 , A61P35/00 , A61P37/06 , C07K14/55 , C07K16/10 , C07K16/28 , C07K16/32 , C07K16/46 , A61K39/00
CPC分类号： C07K14/5428 , A61P35/00 , A61P37/06 , C07K14/5406 , C07K14/55 , C07K16/10 , C07K16/1045 , C07K16/2803 , C07K16/2863 , C07K16/2896 , C07K16/32 , C07K16/464 , A61K38/00 , A61K2039/505 , A61K2039/545 , C07K2317/53 , C07K2317/565 , C07K2317/622 , C07K2317/92 , C07K2319/30
摘要： The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
-
公开(公告)号：US20240335537A1
公开(公告)日：2024-10-10
申请号：US18681931
申请日：2022-08-12
IPC分类号： A61K39/00 , A61K38/00 , A61P35/00 , C07K14/54 , C07K14/55 , C07K14/705 , C07K14/71 , C07K14/715
CPC分类号： A61K39/4635 , A61K39/4611 , A61K39/4613 , A61P35/00 , C07K14/5418 , C07K14/5443 , C07K14/55 , C07K14/70578 , C07K14/71 , C07K14/7155 , A61K38/00
摘要： Disclosed herein are methods and compositions for modulating immune responses by using decoy molecules to bind to soluble or other ligands. In specific embodiments, the decoy molecules comprise a domain that binds to a target immunosuppressive ligand and another domain that releases immunostimulatory signals when activated. In specific embodiments, the decoy molecules are soluble and are secreted by transgenic T cells at a tumor site, such as upon antigen engagement, and they protect the transgenic cells themselves and also bystander (e.g., non-modified) endogenous immune cells.
-
公开(公告)号：US20240327486A1
公开(公告)日：2024-10-03
申请号：US18627761
申请日：2024-04-05
申请人： Amgen Inc.
发明人： Eric Alan BUTZ , Christy Ann THOMSON , Marc Alain GAVIN , Ian Nevin FOLTZ , Dong XIA , Dina N. ALCORN , Randal Robert KETCHEM , Ai Ching LIM , Kathy MANCHULENKO , Laura SEKIROV , Kelly Ann BERRY , Cyr Clovis Chua DE IMUS , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Li LI
CPC分类号： C07K14/55 , A61K38/2013 , A61P37/00 , C07K16/246 , C07K2317/21 , C07K2317/41 , C07K2317/524 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30
摘要： Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US20240327485A1
公开(公告)日：2024-10-03
申请号：US18627094
申请日：2024-04-04
申请人： Amgen Inc.
CPC分类号： C07K14/55 , C07K16/00 , A61K38/00 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/94 , C07K2319/21 , C07K2319/30 , C07K2319/43
摘要： Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
公开(公告)号：US20240317815A1
公开(公告)日：2024-09-26
申请号：US18736261
申请日：2024-06-06
申请人： Cue Biopharma, Inc.
发明人： Anish Suri , Raymond J. Moniz
IPC分类号： C07K14/005 , A61K38/00 , C07K14/55 , C07K14/74 , C07K16/28
CPC分类号： C07K14/005 , C07K14/55 , C07K14/70539 , C07K16/2803 , A61K38/00 , C07K2317/52 , C07K2317/622 , C12N2770/20022
摘要： The present disclosure provides T-cell modulatory multimeric polypeptides (TMMPs) that comprise (i) an optional immunomodulatory polypeptide such as a variant IL-2 polypeptide, (ii) class I HLA major histocompatibility complex (MHC) polypeptides (a class I HLA heavy chain polypeptide and a β2 microglobulin polypeptide), (iii) a peptide that presents an epitope to a T-cell receptor, which together with the class I MHC polypeptides forms a peptide-MHC complex (pMHC), (iv) a tumor-targeting polypeptide, and (v) an optional Ig Fc polypeptide or other scaffold. Such TMMP is useful for modulating the activity of a T cell, and for modulating an immune response in an individual, and for “redirecting” a patient's repertoire of antiviral T cells to attack and kill cancer cells.
-
公开(公告)号：US20240307536A1
公开(公告)日：2024-09-19
申请号：US18271883
申请日：2022-01-11
发明人： Amnon PELED , Inbal MISHALIAN
IPC分类号： A61K39/00 , A61P35/02 , C07K14/54 , C07K14/55 , C07K14/705 , C07K14/715 , C07K16/28 , C12N5/0783 , C12N9/64
CPC分类号： A61K39/4611 , A61K39/4631 , A61K39/4635 , A61K39/464402 , A61K39/464412 , A61P35/02 , C07K14/5443 , C07K14/55 , C07K14/7056 , C07K14/7158 , C07K16/2803 , C07K16/2866 , C12N5/0638 , C12N9/6467 , C12Y304/21079 , A61K2239/26 , A61K2239/48 , C07K2317/622 , C07K2317/73 , C12N2501/2302 , C12N2501/515 , C12N2510/00
摘要： The present invention is directed to the field of immunotherapy. Specifically, the invention provides improved cell compositions and methods for adoptive cell therapy, useful in the treatment of cancer. More specifically, embodiments of the invention employ the use of cell compositions comprising a high proportion of activated cytotoxic CD8+ cells and in particular CD8+NKG2D+granzyme-B+ cells characterized by enhanced cytotoxicity, to processes for their preparation from peripheral blood mononuclear cells (PBMC), and to their use in cancer management.
-
公开(公告)号：US12091441B2
公开(公告)日：2024-09-17
申请号：US17320174
申请日：2021-05-13
CPC分类号： C07K14/55 , A61P37/00 , C07K16/244 , C12N15/63 , A61K9/0024 , A61K38/00 , C07K2317/74 , C07K2317/92 , C07K2319/30 , C07K2319/31
摘要： Provided herein, inter alia, are human interleukin-2 (IL-2) muteins or variants thereof. In particular, provided herein are IL-2 muteins that have a decreased binding capacity for IL-2Rγ. Such IL-2 muteins are useful, for example, as IL-2 partial agonist in applications where reduction or inhibition of one or more IL-2 and/or IL-15 functions is useful (e.g., in the treatment of autoimmune diseases or conditions). Also provided are nucleic acids encoding such IL-2 muteins, methods of making such IL-2 muteins, pharmaceutical compositions that include such IL-2 muteins and methods of treatment using such pharmaceutical compositions.
-
公开(公告)号：US12070474B2
公开(公告)日：2024-08-27
申请号：US17585126
申请日：2022-01-26
IPC分类号： A61K38/20 , A61K35/13 , A61K35/17 , A61K38/17 , C07K14/54 , C07K14/55 , C07K14/705 , C12N5/0783 , A61K35/12
CPC分类号： A61K35/17 , A61K35/13 , A61K38/177 , A61K38/20 , A61K38/2013 , C07K14/54 , C07K14/5434 , C07K14/55 , C07K14/70525 , C07K14/70596 , C12N5/0646 , A61K2035/124 , C12N2500/84 , C12N2501/2302 , C12N2501/2321 , C12N2501/599
摘要： Disclosed herein are novel compositions and methods for stimulation of and the production or expansion of natural killer (NK) cells. Numbers of NK cells can be increased following contact with exosomes modified with one or more stimulatory peptides. Methods and compositions for the production of exosomes, wherein the exosomes comprises stimulatory peptides are also described. Also described are methods of treating cancer using the disclosed NK-stimulating exosomes or NK cells stimulated by the disclosed methods.
-
公开(公告)号：US12049485B2
公开(公告)日：2024-07-30
申请号：US17275662
申请日：2019-09-11
申请人： Ambrx, Inc.
发明人： Sigeng Chen , Yingchun Lu , MD Harunur Rashid , Nickolas Knudsen , Feng Tian
CPC分类号： C07K14/55 , A61K38/2013 , A61K47/60 , A61K38/00
摘要： The present invention provides methods for targeting interleukin-2 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using an interleukin-2 (IL-2) variant conjugated to a biologically active molecule that will affect cells expressing the interleukin-2 receptor.
-
-
-
-
-
-
-
-
-
搜索结果
1086 条记录 (耗时 0.054 秒)
